{"id":596256,"date":"2022-04-18T17:04:02","date_gmt":"2022-04-18T17:04:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=596256"},"modified":"2022-04-18T17:04:02","modified_gmt":"2022-04-18T17:04:02","slug":"ankylosing-spondylitis-pipeline-insights-analysis-into-the-clinical-trials-treatment-algorithm-novel-and-emerging-therapies-key-companies-pfizer-merck-abbvie-kyowa-kirin-and-ucb-biopharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ankylosing-spondylitis-pipeline-insights-analysis-into-the-clinical-trials-treatment-algorithm-novel-and-emerging-therapies-key-companies-pfizer-merck-abbvie-kyowa-kirin-and-ucb-biopharma_596256.html","title":{"rendered":"Ankylosing Spondylitis Pipeline Insights &#8211; Analysis into the Clinical Trials, Treatment Algorithm, Novel and Emerging Therapies | Key Companies &#8211; Pfizer, Merck, Abbvie, Kyowa Kirin, and UCB Biopharma"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Ankylosing Spondylitis Pipeline Insights - Analysis into the Clinical Trials, Treatment Algorithm, Novel and Emerging Therapies | Key Companies - Pfizer, Merck, Abbvie, Kyowa Kirin, and UCB Biopharma\" src=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" alt=\"Ankylosing Spondylitis Pipeline Insights - Analysis into the Clinical Trials, Treatment Algorithm, Novel and Emerging Therapies | Key Companies - Pfizer, Merck, Abbvie, Kyowa Kirin, and UCB Biopharma\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cAnkylosing Spondylitis Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ankylosing Spondylitis Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Ankylosing Spondylitis Pipeline report<\/strong> embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers a detailed description of the drug including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Ankylosing Spondylitis Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/29ddf6ee4795f1a23e2817b8a746f902.jpg\" alt=\"Ankylosing Spondylitis Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Ankylosing Spondylitis Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Ankylosing Spondylitis<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the <strong>Ankylosing Spondylitis Treatment<\/strong>.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Ankylosing Spondylitis key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Ankylosing Spondylitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the <strong>Ankylosing Spondylitis market<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample PDF Report &#8211; @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Ankylosing Spondylitis Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Currently, the cure for Ankylosing Spondylitis is not available in the market, and the available therapies mainly help to reduce the discomfort, pain, and inflammation caused by Ankylosing Spondylitis. <\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>However, currently, several key companies are actively working in the&nbsp;Ankylosing Spondylitis Therapeutics Market. The launch of the emerging therapies is expected to change the treatment algorithm in the coming years.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Ankylosing Spondylitis Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pfizer<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Merck<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Abbvie<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Kyowa Kirin<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">UCB Biopharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Galapagos NV<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sun Pharmaceuticals&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Ankylosing Spondylitis Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tofacitinib&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bimekizumab&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Filgotinib<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tildrakizumab&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Upadacitinib&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">KHK4827<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &#8211;&nbsp; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Ankylosing Spondylitis&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Ankylosing Spondylitis Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Ankylosing Spondylitis &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Ankylosing Spondylitis Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Ankylosing Spondylitis Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Ankylosing Spondylitis Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Ankylosing Spondylitis Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Ankylosing Spondylitis Key Companies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Ankylosing Spondylitis Key Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Ankylosing Spondylitis Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Ankylosing Spondylitis Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Ankylosing Spondylitis Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other&nbsp;Latest Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/injectable-drug-delivery-devices-market\">Injectable Drug Delivery Devices Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The &ldquo;<strong>Injectable Drug Delivery Devices Market<\/strong>&rdquo; is expected to reach <strong>USD 33.37 billion<\/strong> by 2026. Some of the key MedTech companies such <em>Eli Lilly and Company, Biocon, Becton, Dickinson &amp; Company, West Pharmaceutical Services, Johnson &amp; Johnson, Antares Pharma, AbbVie, Pfizer, Mylan N.V., Vetter Pharma-Fertigung GmbH,<\/em> and others are actively working in the Injectable Drug Delivery Devices Market.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75613.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=ankylosing-spondylitis-pipeline-insights-analysis-into-the-clinical-trials-treatment-algorithm-novel-and-emerging-therapies-key-companies-pfizer-merck-abbvie-kyowa-kirin-and-ucb-biopharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=ankylosing-spondylitis-pipeline-insights-analysis-into-the-clinical-trials-treatment-algorithm-novel-and-emerging-therapies-key-companies-pfizer-merck-abbvie-kyowa-kirin-and-ucb-biopharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP \u201cAnkylosing Spondylitis Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ankylosing Spondylitis Market. The Ankylosing Spondylitis Pipeline report embraces in-depth commercial and clinical assessment &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/ankylosing-spondylitis-pipeline-insights-analysis-into-the-clinical-trials-treatment-algorithm-novel-and-emerging-therapies-key-companies-pfizer-merck-abbvie-kyowa-kirin-and-ucb-biopharma_596256.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,417,406,403,404],"tags":[],"class_list":["post-596256","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/596256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=596256"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/596256\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=596256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=596256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=596256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}